BIOGEN INC.

BIIB | Nasdaq | CIK: 0000875045 | SIC: 2836 Biological Products, (No Diagnostic Substances) | active
Biogen Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies for neurological and other serious diseases. Key marketed products include LEQEMBI (Alzheimer's disease), SKYCLARYS (Friedreich's ataxia), and TYSABRI. The company also develops biosimilars and has a pipeline including felzartamab, litifilimab, and salanersen, with collaborations with partners such as Eisai and Supernus.
neurologyrare-diseasesbiosimilarsbiopharmaceuticals
AI agents: Get this data as structured JSON (~200 tokens):
https://origin.rootz.global/api/company/BIIB
Profile | Timeline | SEC Filings | People

Products

NameTypeDescription
LEQEMBIserviceTherapy for Alzheimer's disease developed in collaboration with Eisai.
SKYCLARYSserviceTreatment for Friedreich's ataxia, acquired through acquisition of Reata.
TYSABRIserviceMarketed therapy facing potential biosimilar competition.
TECFIDERAserviceMarketed therapy facing generic competition.
felzartamabservicePipeline candidate acquired through acquisition of HI-Bio.
litifilimabservicePipeline candidate under development.
salanersenservicePipeline candidate under development.

Partnerships

PartnerTypeDescription
EisaidevelopmentCollaboration on development and commercialization of LEQEMBI for Alzheimer's disease.
SupernusdevelopmentCollaboration on pipeline or commercialization programs.
AlcyonestrategicAcquisition for drug delivery solutions development.

SEC Filings

View all SEC EDGAR filings: EDGAR Company Page

Structured filing index: /api/company/BIIB/filings

Origin — Data Provenance
This profile was extracted from SEC EDGAR filings (PEM-signed by sec.gov).
Every API response includes a cryptographic origin leaf for chain-of-custody tracking.
AI Discovery Document | Registry Metrics | GitHub